A clinical team within a leading pharmaceutical company wanted to design a clinical trial for a new combination therapy that would be used to treat a rare disease with an average life expectancy of one year. They determined that a critical part of the protocol design would involve engaging global payers.
Compared to the existing first-line treatment option, the combination treatment was expected to reduce the incidence of relapse and improve the quality of life for patients. However, it was not expected to improve life expectancy, a key consideration for payer organizations.
To gauge the economic viability of the new treatment, the company needed to understand how global payer organizations would consider the quality of life in this disease area and where the new treatment might be placed in formularies.